F2G Employee Directory
Biotechnology ResearchEngland, United Kingdom51-200 Employees
F2G is a clinical-stage biopharmaceutical company based in Manchester, United Kingdom, focused on discovering and developing therapies for life-threatening invasive fungal infections. It has built a portfolio around a new class of antifungal agents called orotomides, which inhibit fungal dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine biosynthesis. Its leading candidate, olorofim, has demonstrated fungicidal activity against a broad range of mould infections, including rare and resistant species that pose treatment challenges. Global Phase 3 enrollment in the OASIS trial has been completed, comparing olorofim to liposomal amphotericin B followed by standard of care in invasive fungal disease due to Aspergillus species. F2G is headquartered in the UK with subsidiaries in the US and Austria. Orphan drug status from the EMA and regulatory designations from the FDA underscore the potential clinical niche of olorofim.
1-888-653-2347 
support@leadiq.com 
